The average selling price for PROMUS PREMIER in Switzerland dropped in 2022, according to GlobalData. The average selling price, the complete price range of high and low prices and a 3-year forecast for the PROMUS PREMIER device in Switzerland can be viewed in GlobalData’s micro pricing report. Buy the report here.
The PROMUS PREMIER is sold by Boston Scientific in the Coronary Stents – DES market. Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.
Factors contributing to the list price of a medical device include but are not limited to therapy area, complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. Moreover, final selling prices vary geographically and by facility type. These prices are further subject to discounts, as well as purchasing and distribution agreements.
For a complete picture of Boston Scientific’ Coronary Stents – DES device pricing in Switzerland, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.